The accumulating evidence of differences in clinical-MRI features, relapse risk, treatment, and outcome led to the concept that patients with MOG antibodies are affected by a distinct syndrome that differs from MS and AQP4-IgG-seropositive NMOSD. This evidence concerns the gene MOG and myeloid sarcoma.